CI

Cogmotos, Inc.

Biotechnology · New York, New York, United States · Founded 2021

About

Cogmotos is a unit of mplexity, inc., an NYC-based biotech venture studio. We use intranasal, direct-to-brain peptide delivery to circumvent (rather than penetrate) the blood-brain barrier. In a recent review of 3,000 papers reporting attempts at intranasal, direct-to-brain drug delivery, the two most-cited papers for either 1) drugs > 1,000 molecular weight or 2) treating CNS disease (in both cases, the disease was Alzheimer’s) involved delivery of insulin with our device platform. This success of intranasal insulin helps our efforts significantly: A) Our Alzheimer’s approach is with brain-biased peptide (BBP) insulin analogues. BBPs are biased toward engaging post-receptor biologic pathways known to preserve cognitive function in CNS disorders, including Alzheimer’s. Our BBPs are easier / less expensive to produce and more stable at room temperature than current insulins. The BBP structures are generated by a machine-learning platform and then validated for stability and CNS-activity bias. Our BBPs have composition-of-matter protection. B) Our post operative delirium program starts with a use-patent-protected delivery of insulin itself. Postoperative delirium (POD) is a critically unmet medical need, afflicting about 25% (1.4 million) of the 5.5 million US patients ≥65 years undergoing major surgery each year. POD is associated with at least $35 billion of incremental cost to the US healthcare system. There are no drugs approved to treat POD, making it perhaps the largest unaddressed disorder of aging. Insulin (delivered with passive-atomizer devices, rather than our computer-controlled delivery platform) has reduced POD incidence >50% in five placebo-controlled trials. Cogmotos is in a position to define the POD market for at least five years post-launch.

Company details may include data from People Data Labs, licensed CC BY 4.0.